The AdaptDx Pro and Theia will change the future of AMD care because they make it easier for eye care professionals to test more patients and diagnose disease at an earlier stage.
Subclinical AMD Detection
Research reveals that impaired dark adaptation is the earliest biomarker of AMD. Diagnosis at the subclinical level is the best chance to preserve vision.
Breakthrough Technology Meets High-Touch Patient Care
Measuring dark adaptation speed with the AdaptDx Pro® can be useful in diagnosing AMD at the subclinical stage and managing this progressive disease with the hope of preventing unnecessary vision loss.
The AdaptDx Pro is amazing for two primary reasons. One, the portability of it is phenomenal. The other piece that’s critical is that Theia, the onboard AI tech, provides the instructions for the test, so patients get consistent instructions every time.
Latest News & Upcoming EventsView More
Dr. Glenn Corbin, one of the earliest adopters of dark adaptation testing in optometric practice, explains how using both structural and functional testing removes the guesswork out of AMD diagnosis and monitoring.
Dr. Glenn Corbin believes eye care providers can diagnose AMD early by implementing protocols that make the transition from suspicion to diagnosis smooth and pleasant for patients. Here’s the protocol used in his practice.
Dr. Claudio Lagunas purchased two AdaptDx Pro devices to keep up with demand. This technology has transformed care in his practice while spurring profitability and allowing his team to make dark adaptation testing the norm, rather than the exception.